PF-06649751 + trimethobenzamide hydrochloride

This is a combination of PF-06649751 (tavapadon), a novel, orally administered, non-catechol-based, highly selective dopamine D1/D5 receptor partial agonist, and trimethobenzamide hydrochloride, an antiemetic agent. PF-06649751 is under investigation for the symptomatic treatment of motor symptoms in Parkinson’s disease and acts by partially activating dopamine D1 and D5 receptors in the brain, possibly providing motor benefit while avoiding side effects of full agonists and older catechol-based D1 agonists[1][3][7]. Trimethobenzamide hydrochloride is used to manage nausea and vomiting, likely by acting on the chemoreceptor trigger zone in the medulla, though its mechanism is not precisely known; it does not primarily act on dopamine or serotonin receptors[2][6][8]. This combination may be investigated to address the nausea commonly associated with dopaminergic therapies.

Brand names

Tigan

Other names

trimethobenzamide HCl